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Anti-CRISPR-mediated control of gene editing and
synthetic circuits in eukaryotic cells
Muneaki Nakamura1,2,3, Prashanth Srinivasan1, Michael Chavez1, Matthew A. Carter1, Antonia A. Dominguez1,2,3,
Marie La Russa1,2,3, Matthew B. Lau1,4, Timothy R. Abbott 1, Xiaoshu Xu1,2,3, Dehua Zhao1,2,3, Yuchen Gao1,5,
Nathan H. Kipniss 1, Christina D. Smolke1, Joseph Bondy-Denomy6,7 & Lei S. Qi 1,2,3
Repurposed CRISPR-Cas molecules provide a useful tool set for broad applications of
genomic editing and regulation of gene expression in prokaryotes and eukaryotes. Recent
discovery of phage-derived proteins, anti-CRISPRs, which serve to abrogate natural CRISPR
anti-phage activity, potentially expands the ability to build synthetic CRISPR-mediated cir-
cuits. Here, we characterize a panel of anti-CRISPR molecules for expanded applications to
counteract CRISPR-mediated gene activation and repression of reporter and endogenous
genes in various cell types. We demonstrate that cells pre-engineered with anti-CRISPR
molecules become resistant to gene editing, thus providing a means to generate “write-
protected” cells that prevent future gene editing. We further show that anti-CRISPRs can be
used to control CRISPR-based gene regulation circuits, including implementation of a pulse
generator circuit in mammalian cells. Our work suggests that anti-CRISPR proteins should
serve as widely applicable tools for synthetic systems regulating the behavior of eukaryotic
cells.
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CRISPR systems, a form of prokaryotic adaptive immunity,have been widely repurposed for biotechnological appli-cations, including genome editing and gene expression
regulation in prokaryotic and eukaryotic organisms1,2. While
these technological advances bring potential benefits to medicine,
agriculture, and the environment, concomitant concerns arise
over the largely irreversible outcomes generated by genome
editing. Means to safely and reversibly control the activity of
CRISPR tools can mitigate security concerns related to their
accidental or intentional misuse. However, the tools available to
effectively counteract gene editing or gene regulation remain
limited.
Synthetic circuits controlling gene expression are another area
of active interest for programming novel cellular behaviors, such
as controlling development or implementing biological sensors
and devices3,4. Recently, interest in synthetic circuits imple-
mented by CRISPR systems5,6 has grown due to the adaptability
of CRISPR-based gene regulation. The complexity of implemen-
table circuits is limited by the types of control nodes that can be
wired to control CRISPR systems. To this end, methods of exo-
genous control over CRISPR systems have been developed7–12,
but internally programmed methods of control remain sparse.
The discovery of a set of bacteriophage proteins, anti-CRISPRs
(Acrs), that inactivate certain CRISPR systems revealed the
existence of an evolutionary arms race between these adaptive
immune systems and infectious agents13; however, it was not
until fairly recently that Acrs targeting the Class II CRISPR sys-
tems, including the protein mostly widely used for genomic
engineering, S. pyogenes (Spy) CRISPR-associated protein 9
(Cas9), were identified14,15. Based on these reports and biophy-
sical and biochemical analyses16–18, a picture has emerged by
which these new Acrs can inhibit CRISPR activity by a variety of
mechanisms and with varying promiscuity, but predominantly
specifically inhibit the binding of a small set of Cas proteins to
DNA. These studies demonstrated inhibition of gene expression
in E. coli cells or extracts15,19, as well as inhibition of genomic
editing14,15,17,20, imaging14,20, or deposition of epigenetic
marks20,21. However, the broad extent as to whether Acrs can be
used as tools to provide temporal, inhibitory control of CRISPR
genome editors and nuclease-deactivated Cas9 (dCas9) genome
regulators (both activation and repression) in different eukaryotic
cells remains to be characterized. In this work, we present a more
complete characterization of Acr activity in a range of contexts
and establish the basis for biotechnological applications involving
the use of Acrs for controlling CRISPR activity in mammalian
cells.
Results
Acrs inhibit CRISPR-based gene regulation in mammalian
cells. CRISPR-based regulation of gene expression involves the
use of a dCas9 with target sequence specified by a single guide RNA
(sgRNA). While DNA binding of dCas9 alone is sufficient for
CRISPR-based gene interference (CRISPRi) in prokaryotes22–24
and yeast25,26, optimal CRISPRi or CRISPR-based gene activation
(CRISPRa) in most eukaryotic organisms involves the fusion of
repressive or activating domains to dCas9, which, when targeted
to a particular locus by an sgRNA, results in specific gene down-
or upregulation25,27. We therefore hypothesized that Acrs that
function through the inhibition of Cas9 binding to DNA should
be able to inhibit CRISPRa and CRISPRi (Fig. 1a), and, con-
versely, we could use these gene regulation tools to further
characterize the function of Acrs.
To do this, we systematically assessed the efficacy of a panel of
5 Acrs (AcrIIC1, AcrIIA1, AcrIIA2, AcrIIA3, AcrIIA4) targeting
Class II CRISPR systems14,15 to alter gene expression changes
induced by CRISPRa and CRISPRi. We co-transfected plasmids
encoding dCas9-effectors, sgRNA, and Acrs into suitable
HEK293T reporter cell lines (Supplementary Fig. 1a). For
CRISPRa, we transfected VPR-dCas9 into a reporter line bearing
the inducible TRE3G promoter driving GFP expression; for
CRISPRi, we used KRAB-dCas9 on a line with an SV40 promoter
driving GFP. For both cell lines, the sgRNA sequence was
designed to target the region of the promoter proximal to the
transcription start site and cells were assessed for induced GFP
reporter expression change.
We observed varying levels of inhibition of CRISPRa and
CRISPRi caused by these Acrs, with AcrIIA4 demonstrating
consistently significant effect in negating CRISPR gene regulation
(Supplementary Fig. 1b-c), which is generally consistent with
results involving CRISPRi in bacteria and editing in human
cells15, as well as the proposed mechanism of AcrIIA4 inhibiting
DNA binding by serving as a DNA mimic16,17.
Based on these results, we further explored the utility of the
best-performing AcrIIA4 in controlling gene regulation. We
designed an optimized version of our assay, wherein the sgRNA
and Acr were incorporated into a single plasmid by fusing the
sgRNA plasmid’s mCherry reporter to the Acr by a self-cleaving
2A peptide (Fig. 1b), using AcrIIC3 (demonstrated to be
ineffective versus S. pyogenes Cas914) as a null Acr. In this assay,
AcrIIA4 almost completely reduced gene up- or down-regulation
to zero, whereas assays performed in the presence of
AcrIIC3 showed similar levels of activity as control assays
(Fig. 1c–e). These results demonstrated that this 2A fusion
strategy can maintain Acr function and CRISPRa and CRISPRi
can be used to quantitate Acr activity.
We subsequently used this 2A fusion strategy to characterize
recently discovered II-A Acr families, AcrIIA528 and AcrIIA629
(Supplementary Fig. 2). With this assay, we were able to
determine that AcrIIA5 proteins demonstrated a modest
(~80%) reduction in dCas9-induced GFP expression, consistent
with a report in yeast30, whereas AcrIIA6 had no discernible
effect.
Acrs can inhibit CRISPRa and CRISPRi on endogenous genes.
We next sought to understand whether AcrIIA4 could be used in
a wider variety of contexts, starting from endogenous gene reg-
ulation. We first created a set of doxycycline (dox)-inducible
CRISPRa and CRISPRi PiggyBac constructs for integration into
HEK293T (Fig. 2a). We used sgRNAs designed to target the
expression of the endogenous C-X-C chemokine receptor type 4
(CXCR4) gene and observed strong CRISPRa (~15-fold increase)
and CRISPRi (~85% decrease) activity (Supplementary Fig. 3a-b,
Fig. 2b). By contrast, AcrIIA4 demonstrated almost total nullifi-
cation of gene regulation activity, while AcrIIC3 showed little
inhibitory effect (Supplementary Fig. 3a-b; Fig. 2b). We observed
that fusing AcrIIA4 N-terminal to the 2A peptide and fluorescent
protein demonstrated slightly stronger anti-CRISPR effect, pos-
sibly due to differences in the coupling efficiency of the 2A
peptide31.
We subsequently tested the applicability of AcrIIA4 in other
cell types. We used a human-induced pluripotent stem cell
(hiPSC) line with our dox-inducible CRISPRa construct knocked
into the AAVS1 locus (Fig. 2c). This cell line was lentivirally
transduced with constructs bearing CXCR4-targeting sgRNA
with and without AcrIIC3 and AcrIIA4. Consistently, we
observed minimal effects on gene regulation with AcrIIC3 and
strong inhibition of CRISPRa with AcrIIA4 (Supplementary
Fig. 3c; Fig. 2d). This suggests AcrIIA4 works for controlling
CRISPR-based gene regulation in diverse mammalian cell types as
a general tool.
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Acrs inhibit CRISPR activity in yeast cells. We next investigated
the efficacy of Acrs in other eukaryotic systems. S. cerevisiae is a
common metabolic engineering platform and also provides a
useful system for protein engineering. We first assessed the
activity of our Acr panel using a yeast editing assay, in which
yeast cells were co-transformed with a plasmid bearing Cas9,
sgRNA targeting essential gene TRP1, and a KanMX selection
marker alongside a plasmid bearing Acr genes (Fig. 3a). Cells
could only survive on selection plates with active Acr inhibiting
Cas9. Multiple type II-A Acrs were found to be effective in
abrogating CRISPR activity (Fig. 3b, c), including AcrIIA1, which
showed minimal effect in our mammalian CRISPRa and CRISPRi
assays or previously described CRISPRi and editing assays15.
To further understand the function of Acrs in yeast, we also
tested their activities on CRISPRa and CRISPRi using a pair of
reporter strains and transforming a plasmid bearing sgRNA and
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Fig. 1 CRISPR-based gene regulation provides quantitative characterization of Acr activity. a Gene regulation mediated by sgRNA-programmed binding of
dCas9 fused with gene activation domain VPR (CRISPRa) and gene repression domain KRAB (CRISPRi). Acrs that inhibit binding of DNA should prevent
CRISPRa and CRISPRi. b Box diagrams for experimental assay of Acr activity: cell lines with integrated reporter for CRISPRa (top) and CRISPRi (bottom) are
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positive control (dCas9 effector+ active sgRNA) conditions in absence of Acr are compared to conditions with AcrIIC3 or AcrIIA4 incorporated in active
sgRNA plasmid. Dotted line indicates median value of non-targeting sgRNA negative control. e Summary comparison of CRISPRa and CRISPRi activity in
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Acr (Fig. 3d). Consistently, we found that plasmids containing
AcrIIA3 were toxic, even when transformed without dCas9
(Supplementary Fig. 4a). AcrIIA3 was previously found to be
toxic in bacteria15, indicating that a common mechanism may
underlie its biological effects. Other Acrs demonstrated a
consistent effect on CRISPRa and CRISPRi (Supplementary
Fig. 4b; Fig. 3e). Interestingly, all tested II-A Acrs were effective,
except for AcrIIA1. These assays in concert suggest the following
results: AcrIIA1 is a strong inhibitor of Cas9 editing in yeast but
not dCas9-based gene regulation, implying a possible mechanism
of inhibition at the editing level (perhaps akin to a previously
reported mechanism for a II-C Acr18); and AcrIIA2 demonstrates
stronger apparent activity for gene editing and gene regulation in
yeast than in mammalian cells (consistent with other
reports30,32).
Acrs negate activity of CRISPR-based synthetic devices. We
subsequently examined the use of Acrs in inducible gene reg-
ulation systems. We recently reported a G-protein-coupled
receptor (GPCR)-activated dCas9 gene regulation system (Cha-
Cha system)8, which combines a GPCR fused to tobacco etch
virus protease (TEV) and V2 vasopressin tail and a dCas9-VPR
fused to β-arrestin via a TEV cleavage site (TCS). GPCR activa-
tion by cognate ligand binding induces recruitment of β-arrestin,
which allows for release of dCas9-VPR for nuclear localization
and gene activation. We incorporated AcrIIA4 into the ChaCha
system via a variety of linkers—3xGlySer, P2A, nuclear localiza-
tion signal (NLS) and destabilization domain (DD)—downstream
of the GPCR construct (Fig. 4a). While control ChaCha assays
demonstrated ligand-inducible gene activation, all of our AcrIIA4
fusions completely inhibited the synthetic device in both on and
off states (Fig. 4b).
To further understand the nature of this effect, we tested the
same set of constructs with a free dCas9-VPR control
(Supplementary Fig. 5a) and again obtained significant reductions
in activation (Supplementary Fig. 5b). By contrast to our Acr
ChaCha and previous Acr CRISPRa assays, there remained
residual (3- to 8-fold) activation. By comparing the performance
of the identical (after cleavage) P2A-AcrIIA4 construct in this and
our previous Acr CRISPRa assays, these results can most likely be
at least partially explained by the difference in stoichiometric
ratios: the CMV (strong) and PGK (weak) promoters are
switched (and the GPCR-TEV-P2A-BFP construct is much larger
than the mCherry fused to AcrIIA4 in Fig. 1). This idea that
relative stoichiometry may play a role in overall activity was
corroborated by an experiment wherein dCas9-VPR and Acr are
produced from the same plasmid in roughly a 1:1 ratio
(Supplementary Fig. 5c), resulting in similar amounts of
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significant, but not total, downregulation of gene expression
(Supplementary Fig. 5d).
Based on these combined results, the performance of various
Acr fusions can be assessed: fusing AcrIIA4 to NLSx2 seems to
diminish its performance, even relative to a BFP fusion (GSx3
linker), and, in accordance with expectations, fusing DD reduces
performance further. Similarly, the stronger performance of these
construct variants on the ChaCha assay relative to the free dCas9-
VPR assay seems to imply that active free dCas9-VPR molecules
in the ChaCha assay (after protease cleavage) are produced in
lower amounts relative to constitutive expression of the free
dCas9-VPR. We also tested a P2A-NLSx2-AcrIIA2 construct,
which showed no inhibition of CRISPRa even in the ChaCha
assays, implying that this construct is almost completely inactive.
The results suggest that switching between experimental or
construct configurations might allow for deeper quantitative
understanding of both CRISPR-based devices and anti-CRISPR
activity.
Inducible Acrs allows dosable control of CRISPR activity. We
further engineered Acrs for inducible control of gene expression.
To do this, we fused an engineered inducible destabilization
domain (DD)33 to AcrIIA4 (Fig. 4c). Addition of cognate
ligand Shield1 stabilizes DD and the fused AcrIIA4, leading to
stronger inhibition of dCas9 activity. We tested the DD-AcrIIA4
constructs using our reporter CRISPRa assay and observed
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Shield1-dependent switch behavior (Fig. 4d), while normal
CRISPRa or Acr lacking DD showed no response (Supplementary
Fig. 6a,c). Fusing DD to the N-terminus of AcrIIA4 showed
Shield-1-inducible gene expression, while fusing DD to the
C-terminus was ineffective, possibly due to the reduced amount
of induced degradation provided by DD at the C-terminus34. We
also observed no change in activation with a DD-VPR-dCas9
construct (Supplementary Fig. 6b,c). A DD-Cas9 was previously
shown to have inducible editing activity;35 the difference possibly
lies in the increased size of the VPR-dCas9 construct and the
delivery method (transient transfection versus viral transduction).
Notably, another DD variant was found to be ineffective in
modulating gene expression when fused to dCas9 in another
study12, further corroborating that DD provides incomplete
control over dCas9-based effector function. These results
demonstrate the utility of AcrIIA4 as an easily incorporable and
modular tool for engineering inducible dCas9 activity, requiring
no re-engineering of the dCas9 construct (and demonstrating
superior performance in at least certain contexts).
Acrs offer a means to genomically write-protect cells. With the
broad use of CRISPR for multiple purposes in diverse organisms,
including gene editing to correct diseases, generation of geneti-
cally modified organisms (GMOs), and field testing of gene drives
to eliminate species, it remains a major need to devise new
countermeasures that provide prophylactic options to limit gen-
ome editing in organisms and protect genome integrity in
populations of organisms. Therefore, we tested whether human
cells pre-engineered with Acr molecules become resistant to gene
editing, which results in a genome with “write protection” against
specific Cas9s.
We first tested the efficacy of AcrIIA4 in a HEK293T reporter
system for gene editing and noted that co-transfection of AcrIIA4
plasmid resulted in strong, but not total inhibition of gene editing
(Supplementary Fig. 7). We then stably integrated a lentiviral
construct encoding AcrIIA4 into the genome of HEK293T cells
(Fig. 5a), generating write-protected cells (WPCs). We tested gene
editing in WPCs compared to wild-type HEK293T cells by
delivering Cas9 and a sgRNA targeting various genomic loci.
Using a plasmid delivery method followed by T7E1 assay, we
observed no editing in WPC cells pre-engineered with AcrIIA4,
while wild-type HEK293T cells exhibit strong gene editing
(Fig. 5b). We further compared various delivery methods using
plasmids, with or without subsequent sorting, and ribonucleo-
protein complexes (RNPs), and in all cases gene editing in
AcrIIA4-engineered WPC cells was negligible with a similar level
below the detection limit of Tracking of Indels by Decomposition
(TIDE) analysis36 (Fig. 5c). Our data prove the feasibility of this
approach of generating “write protection” in cells to counteract
further gene editing, thus laying a foundation to prevent
accidental or intentional gene editing in desired cell types.
Acr-based genetic circuits provide pulsatile gene expression.
Another potential advantage of Acr-based control of gene reg-
ulation is that it lends itself as a method to implement pre-
programmed genetic circuitry. To test this idea, we generated
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3 simple gene regulation circuits (Fig. 6a): CRISPRa (VPR-dCas9-
driven GFP expression), Acr (VPR-dCas9 activity inhibited by
constitutive Acr expression), and an incoherent feedforward loop
(IFFL) circuit (VPR-dCas9 driving both GFP and Acr expression,
resulting in delayed abrogation of CRISPRa activity). To observe
the effects of these circuits in a time-dependent manner, we stably
integrated a plasmid containing sgRNA and appropriate Acr
construct and triggered the circuit via transient transfection of
VPR-dCas9 plasmid (Supplementary Fig. 8a). The resulting
changes in expression of GFP were tracked by live-cell time-lapse
microscopy. Though individual cells exhibited heterogeneous
responses, clear qualitative differences in phenotypes among the
different circuits were evident (Supplementary Movies 1–3).
To more quantitatively understand the behavior of the circuits,
we implemented an unbiased automated cell tracking image
analysis pipeline, allowing us to follow the GFP trajectory of a cell
(or a cluster of cells) over time (Fig. 6b; Supplementary Movie 4).
By tracking the GFP fluorescence of these cells, we observed clear
CRISPRa and anti-CRISPRa phenotypes in the combined
population for the CRISPRa and Acr conditions, while the IFFL
condition demonstrated intermediate GFP expression (Supple-
mentary Fig. 8b). In contrast to the CRISPRa and Acr circuits,
expression of mCherry remained low throughout activation of the
IFFL circuit (Supplementary Fig. 8c), suggesting that a relatively
small amount of AcrIIA4 is sufficient to effect reversal of
CRISPRa activity in the IFFL case.
We hypothesized that the GFP signal in the bulk population
from the IFFL circuit was diluted by variation in the onset time of
the circuit, wherein different cells activate at different times
(Fig. 6b; Supplementary Movies 3–4), most likely due to
biological variation and stochastic differences in delivery time
of the circuit-activating VPR-dCas9 plasmid. To account for this
variation, we fit each cellular trajectory to an asymmetric gaussian
function, allowing for the alignment of these traces in time
relative to the peak point of response. The aligned traces
demonstrated a pulse-like phenotype of GFP expression for the
IFFL condition (Fig. 6c), whereas a similar alignment procedure
revealed sigmoidal behavior with high or low amounts of GFP
expression for the CRISPRa and Acr conditions, respectively
(Supplementary Fig. 8d).
Based on fits to the IFFL condition, we estimated descriptions
of average circuit response, including pulse width (half-rise time
~6 h, half-decay time ~10 h) and amplitude (peak expression ~5-
fold relative to basal level). We also tested the IFFL condition
without stably integrating the sgRNA plasmid and observed
similar pulse behavior in a percentage of cells (Supplementary
Fig. 8e), indicating the possibility of achieving programmed
circuit behavior solely via transient delivery of DNA. The ability
to implement “pulse generator” circuits using Acrs highlights
their utility in synthetic circuit engineering, which could provide
a powerful method to control genes in a highly programmable
and dynamic manner.
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We built a simple computational model in order to further
understand the basis of the IFFL circuit behavior (Supplementary
Methods). We parameterized the model via sequential fits to
experimental data and were able to recapitulate the qualitative
behavior of all three implemented circuits (Supplementary Fig. 9).
We subsequently generated theoretical predictions of the effects
of perturbing various parameters on the performance of the
circuit (Fig. 6d–j). Notably, parameters such as VPR-dCas9 and
Acr production rate, as well as Acr strength of interaction, were
predicted as major factors that control amplitude of the generated
pulse. These results provide semi-quantitative predictions of how
circuit behavior may be rationally altered and lay the groundwork
for further implementation of genetic circuits with tunable
dynamics and responses.
Discussion
In this work, we evaluated and characterized a panel of natural
phage-derived anti-CRISPR proteins using both CRISPRi and
CRISPRa in mammalian cells. Our results demonstrated that
AcrIIA4 is a potent regulator of (d)Cas9 activity in a wide variety
of contexts (reporter or endogenous genes) and cell types
(HEK293T, hiPSC, and yeast). The small size of AcrIIA4 allows it
to be incorporated in a range of contexts easily, and it remains
highly efficient in inhibiting CRISPR activity when fused to other
gene products via many linkers including 2A peptides at either the
N- or C-terminus, or larger domains such as DD or fluorescent
proteins. We also demonstrated that AcrIIA4 is effective in ablating
CRISPR-based complex synthetic devices. Fusing a destabilization
domain to AcrIIA4 enabled tunable and inducible control of
CRISPRa activity. This, combined with other reports14,15,21, con-
tributes to a picture on the use of Acrs as an additional layer of
control over (d)Cas9 activity in eukaryotic cells. Thus, the work
presented here expands the existing CRISPRa / i tool set by
characterizing a useful and tunable inhibitor molecule, which is
useful for probing biology in a wider range of contexts.
The advent of CRISPR technologies has drastically reduced the
barrier of genome editing and control over gene expression. While
undoubtedly a boon to science, this ease of use has also raised
concomitant fears of the use of gene editing for malignant or
otherwise unethical or illegal purposes. Our results are a proof-of-
principle demonstration of the practicality of integrating Acrs in the
genome to generate cells that are immune to unlicensed editing
applications. We also observed that AcrIIA4 could operate when
present at low-copy number (genomically integrated versus tran-
siently transfected), and there was no apparent cytotoxic effect nor
loss of expression of Acr over months of culturing in HEK293T and
hiPSC lines. AcrIIA4 inhibits Spy (d)Cas9, by far the most com-
monly used CRISPR system, but potentially may be bypassed with
another Cas9 ortholog. However, due to the small size of most Acrs,
we believe it would be possible to create a cassette encoding mul-
tiple Acrs targeting commonly used orthologs, especially as the
wealth of Acrs becomes uncovered37–39 or to use promiscuous anti-
CRISPRs18 as broad-spectrum inhibitors.
Based on our results, we anticipate that an integration
approach should also work for defending against Cas9-based
editing in S. cerevisiae; this may be of use to preserve the integrity
of lines used in the production of sensitive materials including
toxic products and controlled substances40. Additionally, we
propose that genomically write-protected organisms may be used
as a safety valve for counteracting CRISPR-based gene drives.
Cas9-driven gene drives have already been implemented in
organisms such as mosquitos41,42, but one major concern is the
potential for unforeseen ecological impacts resulting from
population collapse. We believe that the introduction of a
population with an integrated Acr should inhibit and possibly
allow for the reversal of the spread of the gene drive; indeed, a
proof-of-principle study demonstrated the use of Acrs for the
inhibition of a gene drive in yeast32.
The use of CRISPRa and CRISPRi for assessing Acr activity
relative to editing assays affords a few advantages: the assays are
quick and can provide quantitative information on Acr activity
(rather than a discrete readout of edited / not-edited) on the
single-cell level, and thus are ideal for assessing Acr activity in
eukaryotic cells. Further, the combination of CRISPRa and
CRISPRi assays (in addition to editing assays) allows for distin-
guishing between specific anti-CRISPR activity and potential
cytotoxic effects and revealed that other Acrs demonstrate vary-
ing activity depending on the organismal and CRISPR activity
(knockout versus gene regulation) context. These results suggest
differences in underlying mechanisms in the various Acr families
and open up new lines of inquiry in exploring Acr function. Our
results suggest that we can begin to move from a regime of
classifying Class-II-targeting Acrs in a binary manner as effective
or non-effective into one where anti-CRISPR activity can be more
finely determined. We believe that these assays, coupled with the
feasibility of using such organisms as E. coli and S. cerevisiae,
allow for rapidly screening of discovered or designed Acrs for
enhanced or tuned activity, activity targeting Cas9 variants and
orthologs, and promiscuity of Acr activity; based on the
mechanism of Cas9, novel Acrs that can modulate dCas9 activity
should also prove sufficient for inhibiting Cas9-driven editing.
The use of Acrs in regulating CRISPR activity should allow for
the generation of more advanced dynamic control over gene
regulation. Our results demonstrate that incorporating inducible
control over AcrIIA4 can be superior to using the same tech-
nology directly on Cas9. It is possible that the temporal dynamics
of Acrs under such methods of control would be sharper com-
pared to control over Cas9, because Acr is smaller and can be
likely produced and degraded more quickly. The level at which
Acrs operate is distinct from other methods of inducible
control7,8, allowing for multilayered logical control over dCas9-
based gene regulation. A recent report also demonstrated the
utility of incorporating control on the Acr by realizing light-
dependent activity of Acr20, further cementing this notion of Acr
as an easily adaptable mode of control over (d)Cas9 function.
Furthermore, as inducible control over Acrs and Cas9 function
have opposite relationships, it is likely that implementing control
over both Acrs and Cas9 will allow for inversion of the response
of Cas9 activity relative to the control signal. We suggest that
Acrs will serve as a useful part of developing new methodologies
governing CRISPR activity.
We demonstrate in this report a proof-of-concept pulse gen-
erator circuit implemented via Acr-dCas9 interaction. Although a
similar sort of circuit was previously reported in bacteria43, to our
knowledge, a synthetic pulse response circuit has not been
reported in mammalian cells. Utility of these circuits may be
enhanced by adding additional nodes of control (such as dCas9
orthologs/Acrs or other gene regulation tools) and implementing
control over endogenous genes, as well as computational mod-
eling to analyze and optimize circuit performance. Our work
opens the door to use dCas9 and Acrs to build dynamic pre-
programmed gene regulation circuits and to understand the
behavior of these circuits in a more quantitative manner. With
further investigation, Acrs are poised to enter the realm of
quantitative synthetic biology, potentially integrating multiple
inputs and dCas9 effectors into genetically encoded gene reg-
ulation programs.
Methods
Materials. Plasmids and cell lines were generated using standard molecular
cloning techniques. See Supplementary Tables 1–4 for details on constructs used.
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Cell culture. HEK293T cells (Clontech) were cultured in DMEM+GlutaMAX
(Thermo Fisher) supplemented with 10% Tet-FBS (Clontech). Human iPSCs were
cultured in mTeSR (STEMCELL Technologies). Cells were maintained and pas-
saged using standard cell culture techniques and were maintained at 37 °C and 5 %
CO2. Cells were not regularly monitored for mycoplasma contamination.
Transient transfections were performed using TransIT-LT1 transfection reagent
(Mirus). Lentivirus for generating reporter cell lines and sgRNA transduction was
packaged using wild-type HEK293T (Clontech). Lentiviral transduction was
performed at roughly 0.25 multiplicity-of-infection. Transduced HEK293T cell
lines were sorted in bulk (except for the write-protected cell line, which was
clonally sorted). The cell line containing the IFFL was sorted for negative mCherry
expression, then transfected with a plasmid bearing tetracycline-controlled
transactivator (tTA) and sorted for positive expression 2 days post transfection.
Doxycycline-inducible KRAB-dCas9 and dCas9-VPR HEK293T stable lines were
generated using the PiggyBac transposon system. dCas9-VPR and rtTA were
knocked into the AAVS1 locus in previously generated hiPSCs44 using techniques
as previously described45; briefly, plasmids bearing TALENs targeting the AAVS1
locus were co-transfected along with plasmid containing the VPR-dCas9+ rtTA
construct using the Amaxa Nucleofection system and a clonal population isolated.
Activation experiments were assessed for activity 2 days post transfection;
repression experiments were assessed at 5 days. Doxycycline-inducible constructs
were maintained in medium supplemented with 1 µg/mL doxycycline starting from
the transfection date (except for −dox conditions). For GPCR experiments, cells
were exposed to 20 µM ligand clozapine-N-oxide for 1–2 days before assessing
activity. For DD-Shield1 experiments, medium of cells was supplemented with
appropriate amount of Shield1 ligand immediately following transfection.
Gene regulation flow cytometry and analysis. For CXCR4 expression analysis,
cells were targeted with APC-labeled CXCR4 antibody (BioLegend #306510) before
flow cytometry assays. Analysis of flow cytometry data, including compensation,
was performed using FlowJo. Cells were gated for viability and single cells, as well
as positive fluorescence markers. Fluorescence values were normalized within
experimental runs to an untransfected control. For plotting, values were normal-
ized to the non-targeting sgRNA negative control condition, except for hiPSC data,
which were normalized to the +dox, no sgRNA condition. Unless otherwise stated,
average values provided are geometric means and error bars are ±s.e.m. Sig-
nificance tests and p-values were calculated using two-sided Welch’s t-tests.
Mammalian editing experiments. For gain-of-function editing experiments, a
HEK293T reporter cell line with out-of-frame split-GFP construct was transfected
with Cas9 and sgRNA plasmid with and without plasmid containing AcrIIA4.
Three days after transfection, cells were analyzed via flow cytometry without gating
for presence of plasmid.
For write-protection editing experiments, HEK293T cells were transiently
transfected with plasmid bearing Cas9-eGFP and sgRNA, as above, or Cas9 protein
(IDT or Synthego) with synthetic modified sgRNA (Synthego) via electroporation
(Invitrogen Neon or Amaxa Nucleofection). Plasmid transfections were sorted
1–2 days post-transfection for presence of GFP. Genomic DNA was isolated via
spin-column chromatography (Qiagen), amplified at target locus via PCR (Kapa
Biosystems), and assessed via T7E1 endonuclease activity (NEB) or TIDE
sequencing analysis36. Sequencing traces (Quintara Biosciences) were compared to
untransfected conditions to determine editing efficiency; sequencing traces of
untransfected conditions were compared to each other to determine baseline noise
of the TIDE assay.
Microscopy data and analysis. Cells for microscopy were cultured in FluoroBrite
DMEM medium supplemented with GlutaMAX (Thermo Fisher) and 10 % Tet-
FBS. Cells were transfected as above, and immediately placed in a microscopy
chamber pre-equilibrated and maintained at 37 °C and 5% CO2. Imaging was
performed with an integrated Leica microscopy system. Selected fields of view were
automatically imaged for mCherry, GFP, and BFP fluorescence and combined into
time series post-acquisition.
Movies were background-subtracted (ImageJ), and cell-centered traces were
generated by an automated algorithm for computationally tracking spots in the
GFP channel and joining identified spots into combined tracks (TrackMate). Spots
were filtered by threshold and signal-to-noise ratio, and traces comprising fewer
than 12 spots were automatically discarded. Cell-centered sub-movies were
generated on remaining traces and analyzed via a custom Python script. To
calculate fluorescence for each trace, a 31 pixel (~10 µm) square region was
isolated, and the arithmetic mean of the top 50 % highest intensity pixels was
calculated for each frame of the sub-movie. To perform the fit, these traces were fit
to an asymmetric gaussian function using a trace-specific t0 (center of gaussian)
and amplitude and global minimum value and rate constants governing decay to
the left and right of the center of the curve. To account for spurious detection and
low-signal traces, we applied an iterative filtering process, discarding any traces that
had amplitude less than the minimum value (i.e., lower than 2-fold change) and
then re-performing the fit until convergence.
Yeast experiments. For editing experiments, competent yeast stocks (CEN.
PK2–1D strain) were generated and transformed with standard protocols (Frozen-
EZ Yeast Transformation II Kit, Zymo Research) and were grown at 30 °C in yeast
peptone dextrose (YPD) liquid medium supplemented with 80 mg/L adenine
hemisulfate and YPD-agar plates with 1 g/L monosodium glutamate and 400 mg/L
G418 sulfate. Transformants were recovered for 2 h in YPD before plating with
G418 selection. Colony formation was assessed 48–60 h after plating.
For toxicity experiments, CEN.PK2-1D was transformed with Acr plasmids
alone, as above, plating on synthetic complete agar plates lacking uracil. For
CRISPRa and CRISPRi experiments, reporter strains yJZC10 and yJZC14,
respectively, were transformed with plasmids, as toxicity experiments. Overnight
cultures were back-diluted 1:4 in synthetic complete medium lacking uracil and
assessed 4–6 h later via flow cytometry. Control conditions (strains lacking
plasmid) were transformed and grown in media containing uracil.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data and code that support the findings of this study are available upon request
to the corresponding author (L.S.Q.).
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